Bluesail Medical's Cardiovascular Subsidiary Blue Sail BioScience Secures RMB 1 Billion in Series A2 Funding, Bringing Total Raise to RMB 10 Billion with CEC Capital as Exclusive Financial Advisor

Recently, Blue Sail Medical (002382.SZ) announced that its holding platform for the cardiovascular and cerebrovascular business unit, Blue Sail Bioscience, will secure an additional RMB 100 million in Series A2 financing, following the successful completion of a RMB 900 million Series A1 round in January 2024. This round introduces the Beijing Daxing Airport Economic Zone Development Fund (Limited Partnership) as an investor, marking an accelerated strategic expansion by Blue Sail Medical in the cardiovascular and cerebrovascular sectors.

China Renaissance continued to serve as the exclusive financial advisor to Blue Sail-Biosensors in this transaction. The cumulative amount of this financing round reached RMB 1 billion, setting a new record for the largest single-round private equity financing transaction in China’s medical device sector over the past two years.

This Series A2 financing round not only provides further financial support to Blue Sail Bosheng but will also help the company gradually establish its northern headquarters for high-end medical devices in southern Beijing and the Airport Economic Zone. By aligning with the national strategy for coordinated development of the Beijing-Tianjin-Hebei region, Blue Sail Medical will leverage Beijing’s concentration of medical resources and the policy advantages of the Airport Economic Zone to build an integrated service platform, contributing to the advancement of the life and health industry.